ARVN Stock Overview
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
Arvinas, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$54.46|
|52 Week High||US$98.67|
|52 Week Low||US$34.90|
|1 Month Change||9.25%|
|3 Month Change||28.29%|
|1 Year Change||-40.29%|
|3 Year Change||127.96%|
|5 Year Change||n/a|
|Change since IPO||239.32%|
Recent News & Updates
Arvinas: Still Holding, Just Not Buying More
Arvinas announced decent data from ARV-110 in February. The market may have expected more. I will continue to hold.
|ARVN||US Pharmaceuticals||US Market|
Return vs Industry: ARVN underperformed the US Pharmaceuticals industry which returned 1.3% over the past year.
Return vs Market: ARVN underperformed the US Market which returned -10.2% over the past year.
|ARVN Average Weekly Movement||10.0%|
|Pharmaceuticals Industry Average Movement||12.1%|
|Market Average Movement||7.7%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: ARVN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ARVN's weekly volatility (10%) has been stable over the past year.
About the Company
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG.
Arvinas, Inc. Fundamentals Summary
|ARVN fundamental statistics|
Is ARVN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ARVN income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-4.38|
|Net Profit Margin||-255.87%|
How did ARVN perform over the long term?See historical performance and comparison